AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02656160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 3 hrs before sleep
Study NCT02656160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine
Description: Dalfampridine 10 mg extended release 3 hrs before sleep
Study NCT00473135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated rDEN1delta30 vaccine at a dose of 10\^3 PFU
Study NCT00473135 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN1delta30
Study NCT03411460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre™ system
Description: Measured non-invasively via scanner
Study NCT03411460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Finger prick
Description: Blood test
Study NCT02444481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polygynax combinaison of polymyxin, Neomycin and Nystatin
Study NCT00714597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00714597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection
Study NCT00400985 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.
Description: SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
Study NCT02274194 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP
Description: use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
Study NCT02274194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oronasal CPAP
Description: use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
Study NCT02472769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBP-9414
Study NCT02472769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile water
Study NCT02142660 — intervention group
Intervention type: PROCEDURE
Intervention: ablation of gastric
Description: Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
Study NCT03421093 — intervention group
Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries or surgeries plus adjuvant therapies
Study NCT02262143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 10 mg, qd, po
Study NCT02262143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 10 mg, qd, po
Study NCT02262143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 160mg, qd, po
Study NCT03524300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Total Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.
Study NCT03524300 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Assisted Total Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
Study NCT02302404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 solution
Description: Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
Study NCT02302404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 capsule
Description: Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
Study NCT02302404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo solution
Description: Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
Study NCT02302404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Size 00 White Opaque capsule containing Placebo as white to almost white solid
Study NCT00512304 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: association chemotherapy and radiochemotherapy
Study NCT02498496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
Study NCT02498496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 100 mL of Normal Saline
Study NCT02317081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axetis Inert Coronary Stents
Description: de novo coronary artery stenosis in native vessels
Study NCT03024853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS PAST
Study NCT03024853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS PRESENT
Study NCT03024853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BPS FUTURE
Study NCT03024853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Study NCT00394953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: As prescribed, iv.
Study NCT00394953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms iv / month, starting dose
Study NCT04250987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeediCath(R)
Description: IC SpeediCath ® connected to pressure sensor
Study NCT02335125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Study NCT02335125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Elements
Study NCT02335125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotropic Drugs
Study NCT02335125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Management
Study NCT04371861 — intervention group
Intervention type: DEVICE
Intervention: Peripheral Artery Treatment
Description: Peripheral lesions may be treated by any standard of care methods of treatment.
Study NCT05666388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rescue stenting
Description: Rescue stenting in the severe atherosclerotic stenosis after the failure of intravenous thrombolysis (RES
Study NCT01849666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenprocoumon
Description: 6 mg oral single dose
Study NCT01849666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg bid orally
Study NCT03601533 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Phenol
Description: 1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
Study NCT02171325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Study NCT04626895 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Paxman Scalp Cooling Device
Description: Paxman scalp cooling device
Study NCT01071525 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Niacin\Laropiprant
Description: Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant
Study NCT01071525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin\Laropiprant
Description: Hypercholesterolemic patients with low HDL will receive Niacin\\Laropiprant
Study NCT02120716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Check-Up for Expectant Moms
Description: Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
Study NCT02858349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention
Study NCT02858349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
Study NCT03681951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3145095
Description: GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
Study NCT03681951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
Study NCT04019548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrotomy tube placement
Description: placement of the PEG tube depends on arm
Study NCT04019548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin injection
Description: Two therapeutic regimen allowed:~* Days 1 and 22 : cisplatin 100mg/m2 IV~* Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV
Study NCT04019548 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.
Study NCT03295656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Contrast-enhanced US imaging of the appendix
Study NCT05488223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AGPI ω-3 (Triple Strength Fish Oil®)
Description: The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
Study NCT05488223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AGPI ω-3 + MUFA (avocado oil)
Description: AGPI ω-3 (0.9g) + MUFA (avocado oil) (0.9g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
Study NCT05488223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MUFA (avocado oil) (1.8g)
Description: MUFA (avocado oil) (1.8g) The children met at a clinical studies office every month for the 5 months, in order to exchange the empty bottles for the full ones and review the consumption record sheet and receive their advice on their diet. In case of absence, the children were located to avoid losses. Finally, at each visit, all the children and their parents received counseling to promote the acquisition of healthy habits related to eating and physical activity, but did not indicate caloric restriction diets or undergo exercise programs.
Study NCT02018835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study NCT02018835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: cardiac echography transthoracic
Study NCT02251288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca
Description: MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10\^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
Study NCT02251288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Description: Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
Study NCT02251288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 adjuvant
Description: Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
Study NCT01762722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reduction of inspired oxygen
Description: Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
Study NCT04135417 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV
Description: Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
Study NCT03071926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: 20 mg, qw, first 6 weeks ,every 8 weeks
Study NCT02046824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtra®, Sorin cellsaver
Description: when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
Study NCT02046824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C.A.T.S.®, Fresenius cellsaver
Description: when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
Study NCT02046824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPAT®, Haemonetics, cellsaver
Description: when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
Study NCT02046824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no use of cell saver
Description: When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
Study NCT01013285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT01013285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT01013285 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Study NCT00915733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: 100 mg twice daily for at least 1 month
Study NCT00915733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel (Plavix)
Description: 150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
Study NCT00915733 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: CYP2C19
Description: CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19\*2 (rs4244285, c. 681G>A, p.P227P), and CYP2C19\*3 (rs4986893, c. 636G>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
Study NCT00915733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin (Acetylsalicylic acid)
Description: aspirin 100 mg qd
Study NCT03438851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCatch Platform™
Description: NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
Study NCT02843971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular pressure measurement with the Sensimed triggerfish Device
Study NCT03294109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abdominal wall block with liposomal bupivicaine
Description: Abdominal wall block with liposomal bupivicaine
Study NCT01794923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBU BID
Description: 10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
Study NCT01794923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID
Description: 10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
Study NCT01794923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBU TID
Description: 10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
Study NCT01794923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo TID
Description: 10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
Study NCT01881750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Training (PRT)
Description: 12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
Study NCT01881750 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Parent Education Group (PEG)
Description: 12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
Study NCT01505010 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal denervation
Description: Renal denervation in the intervention group
Study NCT01505010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Renal denervation in the intervention group
Study NCT01626703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminding call
Study NCT04476056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified Nutritional Therapy
Description: Intensified nutritional therapy will begin in the hospital setting and comprises intake of a commercial oral nutritional supplement (Fortimel Compact 2.4, Nutricia) twice per day as well as personalized dietary counselling. After discharge, supplementation will be continued for at least 28 days and if necessary throughout the entire study duration. Likewise, dietary counselling will be provided throughout the entire study period based on the patient's individual need. Dietary counselling is provided either face-to-face during the follow-up visits or remotely via telephone between visits.
Study NCT02024919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary administration of diltiazem
Study NCT00051363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active CPAP
Description: Nightly nasal continuous positive airway pressure (CPAP)
Study NCT00051363 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham CPAP
Description: Sham CPAP machine will be used for participants in the placebo group.
Study NCT02024919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intracoronary injection of 5 mL saline